In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications

By Dansereau Richard J.   Crail Debbie J.   Perkins Alan C.  

Current Medical Research and Opinion, Vol. 24, Iss. 4, 2008-04 ,pp. : 1137-1145

Informa Healthcare

Access to resources Recommend Favorite

Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget’s disease

By Hooper M.   Faustino A.   Reid I.   Hosking D.   Gilchrist N.   Selby P.   Wu M.   Salzmann G.   West J.   Leung A.  

Osteoporosis International, Vol. 20, Iss. 1, 2009-01 ,pp. : 141-150

Springer Publishing Company

Access to resources Recommend Favorite

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study

By Miller Paul D.   Epstein Sol   Sedarati Farhad   Reginster Jean-Yves  

Current Medical Research and Opinion, Vol. 24, Iss. 1, 2008-01 ,pp. : 207-213

Informa Healthcare

Access to resources Recommend Favorite

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)

By Emkey Ronald   Koltun William   Beusterien Kathleen   Seidman Larry   Kivitz Alan   Devas Vipul   Masanauskaite Daiva  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 1895-1903

Informa Healthcare

Access to resources Recommend Favorite

Once-Weekly Treatment of Anemia in Patients with Cancer: A Comparative Review of Epoetins

By  

Oncology, Vol. 68, Iss. 2-3, 2005-07 ,pp. : 122-129

Karger

Access to resources Recommend Favorite